-
Product Insights
New![]()
E Nash PV3 Solar PV Park
E Nash PV3 Solar PV Park is a solar PV project located in North Carolina, United States. The project is owned and being developed by Ecoplexus Inc. The project is expected to come online in 2025. Empower your strategies with our E Nash PV3 Solar PV Park report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase,...
-
Sector Analysis
![]()
Non-Alcoholic Steatohepatitis (NASH) Epidemiology Analysis and Forecast to 2032
Non-Alcoholic Steatohepatitis (NASH) Report Overview In the 7MM, there were 22,036,613 diagnosed prevalent cases of NASH in 2022. The market is expected to grow at an AGR of more than 2% during 2022-2032. The Non-Alcoholic Steatohepatitis (NASH) market research report provides an overview of the risk factors, comorbidities, and global and historical epidemiological trends for NASH in the seven major markets. The report also includes a 10-year epidemiology forecast for the diagnosed prevalence of NASH. NASH Market Outlook, 2022-2032 (Diagnosed...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Ervogastat in Non-Alcoholic Steatohepatitis (NASH)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Ervogastat in Non-Alcoholic Steatohepatitis (NASH)Drug Details:Ervogastat (PF-06865571) is under development for the treatment of non-alcoholic steatohepatitis...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Denifanstat in Non-Alcoholic Steatohepatitis (NASH)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Denifanstat in Non-Alcoholic Steatohepatitis (NASH) Drug Details: Denifanstat (TVB-2640) is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Ozempic in Non-Alcoholic Steatohepatitis (NASH)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Ozempic in Non-Alcoholic Steatohepatitis (NASH) Drug Details: Semaglutide (Ozempic / NN-9535 / NN-9931) is a...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Belapectin in Non-Alcoholic Steatohepatitis (NASH)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Belapectin in Non-Alcoholic Steatohepatitis (NASH) Drug Details: Belapectin (GR-MD-02) is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Icosabutate in Non-Alcoholic Steatohepatitis (NASH)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Icosabutate in Non-Alcoholic Steatohepatitis (NASH)Drug Details:Icosabutate (PRC-4016; PRB-01022) is under development for the treatment of non-alcoholic...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Licogliflozin in Non-Alcoholic Steatohepatitis (NASH)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Licogliflozin in Non-Alcoholic Steatohepatitis (NASH)Drug Details:licogliflozin was under development for the treatment of nonalcoholic steatohepatitis (NASH)...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Efinopegdutide in Non-Alcoholic Steatohepatitis (NASH)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Efinopegdutide in Non-Alcoholic Steatohepatitis (NASH)Drug Details: Efinopegdutide is under development for the treatment of nonalcoholic steatohepatitis,...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Epeleuton in Non-Alcoholic Steatohepatitis (NASH)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Epeleuton in Non-Alcoholic Steatohepatitis (NASH) Drug Details: Epeleuton (AF-102) is under development for the...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.